Could a simple surgery replace chemo for this rare Pregnancy-Related cancer?
NCT ID NCT03703271
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study compares a repeat curettage (a scraping procedure inside the uterus) against standard chemotherapy with methotrexate as the first treatment for women with low-risk gestational trophoblastic neoplasia, a rare cancer that can develop after a molar pregnancy. The goal is to see if the surgery alone can achieve the same cure rates as chemotherapy, potentially avoiding the side effects of chemo. The trial enrolls women with a low WHO risk score who have not yet received any treatment for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Methotrexate
- What this could lead to
- If successful, this could offer a surgery-first option that spares many women from chemotherapy and its side effects.
- What could go wrong
- This is a small, early-phase trial. The curettage may not work for everyone, and some women may still need chemotherapy. Surgical risks include infection or uterine perforation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GESTATIONAL TROPHOBLASTIC NEOPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Weiguo Lv
RECRUITINGHangzhou, Zhejiang, 310006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.